Skip to main content
Premium Trial:

Request an Annual Quote

Sequenom Shares Soar on Down Syndrome Test Results

NEW YORK (GenomeWeb News) – Shares of Sequenom were up nearly 34 percent, to $27.50, in mid-afternoon trading today after the company disclosed yesterday that its SEQureDx test for Down syndrome successfully tested for Trisomy 21 in 219 patients with no false positives or negatives.
 
The company also announced yesterday that it will acquire the CLIA-certified Center for Molecular Medicine for $4 million, putting it on schedule to launch the Down syndrome test in the first half of 2009.  
 
The results disclosed yesterday follow previous positive findings that the company announced in June and support the potential for the test to be used in the first trimester, the company said.
 
Sequenom said that it plans to do additional testing on 3,000 to 5,000 women and the results of this study should be released next June.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.